NDASUBCUTANEOUSSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Drug Shortage Active
OZEMPIC is currently in shortage. Reason: Demand increase. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
OZEMPIC (semaglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for glp-1 receptor agonist [epc]. First approved in 2017.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ozempic (semaglutide) is a GLP-1 receptor agonist administered subcutaneously to treat type 2 diabetes by enhancing insulin secretion and reducing glucagon release in response to elevated blood glucose. It works by mimicking glucagon-like peptide-1, a hormone that regulates blood sugar levels. The drug has become a blockbuster with significant off-label use for weight management.
$9.2BPart D
PeakGrowing
12.3 years to LOEPeak commercial lifecycle with sustained high spending and massive claims volume indicates a mature, resource-rich brand team managing market leadership.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
GLP-1 Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Started Jul 2026
164 enrolled
Muscle WastingObesity & OverweightObesity
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Started Jun 2026
150 enrolled
Pediatric ObesityMetabolic and Bariatric SurgerySemaglutide
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Started Jun 2026
3,000 enrolled
Obesity & Overweight
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Started May 2026
2,500 enrolled
ObesityType 2 Diabetes
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Started May 2026
1,000 enrolled
ObesityOverweightDiabetes Mellitus, Type 2
Worked on OZEMPIC at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.